Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer-Reference-Cited by-同舟云学术

Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer

Published:2017-08 Issue: Volume:34 Page:S104-S107
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Ellis Matthew J.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference14 articles.

1. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18;Fisher;J Clin Oncol,1997

2. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer;Fisher;J Clin Oncol,1998

3. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04);Toi;Cancer Res,2016

4. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial;Ellis;J Clin Oncol,2001

5. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer gene expression signatures: development and clinical significance—a narrative review;Translational Breast Cancer Research;2023-01

2. Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy;Therapeutic Advances in Medical Oncology;2023-01

3. Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors;Contemporary Clinical Trials Communications;2022-12

4. The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats;Andrologia;2022-08-14

5. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study;Breast Cancer Research and Treatment;2022-08-02